Clinical Trials

MainTitle

Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults

This study has been completed
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)


Information provided by (Responsible Party)
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier
NCT03408899

First received: January 18, 2018
Last updated: April 29, 2019
Last Verified: April 2019
History of Changes
Purpose

Purpose

The purpose of this study is to evaluate the safety and pharmacokinetics of PC-1005 gel when used as a rectal microbicide in HIV-uninfected men and women (cis or transgender) with a history of consensual receptive anal intercourse.

Condition Intervention Phase
HIV Infections

Drug : PC-1005 gel
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel) Administered Rectally to HIV-1 Seronegative Adults

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures

  • Frequency of Grade 2 or higher adverse events (AEs) [ Time Frame: Measured through participants' last study visit which will occur at Month 3 to 5, depending on the participant ]
    AEs are defined by the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1, July 2017 and/or Addenda 1, 2 and 3 (Female Genital [Dated November 2007], Male Genital [Dated November 2007] and Rectal [Clarification Dated May 2012] Grading Tables for Use in Microbicide Studies).
  • MIV-150 concentrations in plasma [ Time Frame: Measured through participants' last study visit which will occur at Month 3 to 5, depending on the participant ]
    Descriptive statistics such as the mean and median and corresponding 95% confidence intervals will be used to describe the MIV-150 concentrations in all biological matrices assessed at all scheduled time points
  • MIV-150 concentrations in rectal fluid [ Time Frame: Measured through participants' last study visit which will occur at Month 3 to 5, depending on the participant ]
    Descriptive statistics such as the mean and median and corresponding 95% confidence intervals will be used to describe the MIV-150 concentrations in all biological matrices assessed at all scheduled time points
  • MIV-150 concentrations in rectal mucosal tissue homogenates [ Time Frame: Measured through participants' last study visit which will occur at Month 3 to 5, depending on the participant ]
    Descriptive statistics such as the mean and median and corresponding 95% confidence intervals will be used to describe the MIV-150 concentrations in all biological matrices assessed at all scheduled time points
Secondary Outcome Measures:
  • Percentage of participants who self-report acceptability of PC-1005 gel formulation [ Time Frame: Measured through participants' last study visit which will occur at Month 3 to 5, depending on the participant ]
    Based on participants' self-reports of comfort with gel application, liking the product across doses, and perceived side effects
  • MIV-150 concentrations in vaginal fluid [ Time Frame: Measured through participants' last study visit which will occur at Month 3 to 5, depending on the participant ]
    Descriptive statistics such as the mean and median and corresponding 95% confidence intervals will be used to describe the MIV-150 concentrations in all biological matrices assessed at all scheduled time points

Enrollment: 13
Study Start Date: June 19, 2018
Study Completion Date: April 19, 2019
Primary Completion Date: April 19, 2019 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: PC-1005
All participants will receive 3 single escalating doses of PC-1005 gel during Visits 3, 5, and 7, with a 2-to-6-week washout period between dosing visits. Each participant will be on study for approximately 3 to 5 months.
Drug: PC-1005 gel

PC-1005 (0.002% MIV-150/0.3% zinc acetate in 3.0% carrageenan gel) in 4 mL, 16 mL, and 32 mL doses administered rectally.

Detailed Description:

PC-1005 is a multipurpose prevention technology (MPT) microbicide in development that is active against HIV, HPV, and HSV-2. This study will evaluate the safety and pharmacokinetics of PC-1005 gel when administered rectally.
The study will enroll HIV-uninfected men and women (cis or transgender) with a history of consensual receptive anal intercourse. All participants will receive 3 single escalating doses of rectally administered PC-1005: 4 mL, 16 mL and 32 mL.
The study includes a total of 9 clinic visits and 1 follow-up contact by phone or in person. Participants will receive doses of PC-1005 at Visits 3, 5, and 7. A 2-to-6 week washout period will follow each dosing visit. If no adverse events that preclude continuation to the next dose are identified during this period, participants will receive the next scheduled dose of PC-1005. Participation in this study will last approximately 3 to 5 months.
Study visits will include physical examinations, throat swabs, behavioral assessments and interviews, and collection of blood, urine, rectal tissue, and cervical, vaginal, and rectal fluid.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  

Criteria

Inclusion Criteria:

  • Men and women (cis or transgender) who are 18 years or older at Screening, verified per site standard operating procedure (SOP)
  • Able and willing to provide written informed consent
  • HIV-1/2 uninfected at Screening and Enrollment, per applicable algorithm in the protocol and willing to receive HIV test results
  • Able and willing to provide adequate locator information, as defined in site SOP
  • Available to return for all study visits and willing to comply with study participation requirements
  • In general good health at Screening and Enrollment, as determined by the site Investigator of Record (IoR) or designee
  • At Screening, history of consensual receptive anal intercourse (RAI) at least once in their lifetime per participant report
  • Willing to not take part in other research studies involving drugs, medical devices, genital or rectal products, or vaccines for the duration of study participation (including the time between Screening and Enrollment)
  • Willing to follow abstinence requirements for the duration of study participation (See the protocol for additional information)
  • For participants of childbearing potential: a negative pregnancy test at Screening and Enrollment
  • For participants of childbearing potential: Per participant report at Enrollment, using an effective method of contraception and intending to use an effective method for the duration of study participation; these include:
    • Hormonal methods, excluding vaginal rings
    • Intrauterine device (IUD) inserted at least 42 days prior to Enrollment (but not past the maximum length of recommended usage according to package instructions)
    • Sterilization of participant or partner at least 42 days prior to Enrollment
    • Self-identifies as having sex with women exclusively


    Exclusion Criteria:
  • At Screening:
    • Hemoglobin Grade 1 or higher*
    • Platelet count Grade 1 or higher*
    • White blood count Grade 2 or higher*
    • Aspartate aminotransferase (AST) or alanine transaminase (ALT) Grade 1 or higher*
    • Serum creatinine greater than 1.3x the site laboratory upper limit of normal (ULN)
    • International normalized ratio (INR) greater than 1.5x the site laboratory ULN
    • History of inflammatory bowel disease by participant report
    • * As per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1, July 2017
    • Note: Otherwise eligible participants with an exclusionary test result can be re-tested during the screening process. If a participant is re-tested and a non-exclusionary result is documented within 45 days of providing informed consent for screening, the participant may be enrolled.
  • Known adverse reaction to latex or polyurethane (ever)
  • Anticipated use of and/or unwillingness to abstain from the following medications during study participation:
    • Anticoagulant medications
    • Rectally-administered medications
  • Known adverse reaction to any of the components of the study product
  • Use of pre-exposure prophylaxis (PrEP) for HIV prevention within 1 month prior to Enrollment, and/or anticipated use and/or unwillingness to abstain from PrEP during trial participation
  • Use of post-exposure prophylaxis (PEP) for potential HIV exposure within the 3 months prior to Enrollment
  • Condomless RAI and/or penile-vaginal intercourse with a partner who is known to be HIV-positive or whose status is unknown in the 6 months prior to Enrollment
  • Non-therapeutic injection drug use in the 12 months prior to Enrollment
  • Participation in research studies involving drugs, medical devices, genital or rectal products, or vaccines within 30 days of the Enrollment Visit
  • Gynecologic, genital, or rectal procedure (e.g., tubal ligation, dilation and curettage, piercing, hemorrhoidal resection, polyp removal) 60 days or less prior to Enrollment, or rectal biopsy, 7 days or less prior to Enrollment. Note: Colposcopy and cervical biopsies for evaluation of an abnormal Pap test as well as IUD insertion/removal are not exclusionary. Anoscopy and endoscopy without rectal biopsies are not exclusionary
  • Per participant report, medical records, clinical diagnosis and/or diagnostic testing at either Screening or Enrollment:
    • Diagnosis or treatment of any anogenital sexually transmitted infection (STI) in the past 3 months (including window between Screening and Enrollment)
    • Symptoms, clinical or laboratory diagnosis of active pharyngeal, anorectal infection or reproductive tract infection (RTI) requiring treatment per current Centers for Disease Control and Prevention (CDC) guidelines (http://www.cdc.gov/std/treatment)
    • Current symptomatic urinary tract infection (UTI)
    • Infections requiring treatment include Neisseria gonorrhea (GC), Chlamydia trachomatis (CT) infection, syphilis, active herpes simplex virus (HSV) lesions, anogenital sores or ulcers, or symptomatic genital warts, chancroid, pelvic inflammatory disease (PID), symptomatic bacterial vaginosis (BV), symptomatic vaginal candidiasis, other vaginitis, and trichomoniasis.
    • Note: Otherwise eligible participants with an exclusionary UTI, BV and/or candida finding may be re-tested during the screening process.
    • Note: HSV-1 or HSV-2 seropositive diagnosis with no active lesions is permitted since treatment is not required.
  • Participants who meet any of the following additional criteria will be excluded from the study:
    • Pregnant or breastfeeding at either Screening or Enrollment or planning to become pregnant or begin breastfeeding during study participation. Note: A documented negative pregnancy test performed by study staff is required for inclusion; however, a self-reported pregnancy is adequate for exclusion from screening/enrollment into the study.
    • Last pregnancy outcome 90 days or less prior to Screening
  • Has any other condition that, in the opinion of the IoR/designee, would preclude
informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving study objectives.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03408899

Locations

United States, Alabama
Alabama CRS
Birmingham, Alabama, United States, 35294
United States, Pennsylvania
University of Pittsburgh CRS
Pittsburgh, Pennsylvania, United States, 15213

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators

Study Chair: Craig Hendrix, MD Johns Hopkins University
More Information

More Information


Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)  
ClinicalTrials.gov Identifier: NCT03408899   History of Changes  
Other Study ID Numbers: MTN-037  
  35122  
Study First Received: January 18, 2018  
Last Updated: April 29, 2019  

Studies a U.S. FDA-regulated Drug Product: Yes  
Studies a U.S. FDA-regulated Device Product: No  

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Microbicides

Additional relevant MeSH terms:
HIV Infections

ClinicalTrials.gov processed this data on September 17, 2019
This information is provided by ClinicalTrials.gov.